UTMD Sees Q2 Net Income Dip Amidst Revenue Decline

TL;DR

**UTMD's Q2 dip is a yellow flag; watch for stronger growth or consider other medical device plays.**

AI Summary

UTAH MEDICAL PRODUCTS INC (UTMD) reported a net income of $4.5 million for the six months ended June 30, 2025, a decrease from $5.1 million in the prior year period. Revenue for the six months ended June 30, 2025, was $24.8 million, compared to $25.5 million for the same period in 2024, representing a 2.7% decline. The company's strategic outlook remains focused on its core medical device segments, particularly in obstetrics and neonatology. Key business changes include a slight shift in revenue distribution between domestic and international markets, with domestic revenue at $18.6 million and international at $6.2 million for the first half of 2025. Risks include ongoing competitive pressures in the medical device industry and potential supply chain disruptions, though the filing does not detail specific new risks. The company maintained its capital structure with common stock at $1.2 million and retained earnings at $105.3 million as of June 30, 2025.

Why It Matters

UTMD's slight revenue decline and net income dip signal a challenging competitive landscape for investors, suggesting potential pressure on future dividends or stock performance. For employees, stable operations in core segments like obstetrics and neonatology offer some job security, but overall growth stagnation could limit opportunities. Customers might see continued product availability, but the company's performance indicates it's not aggressively expanding its market share against larger medical device competitors. The broader market for specialized medical instruments remains robust, but UTMD's results highlight the intense competition and the need for innovation to maintain relevance.

Risk Assessment

Risk Level: medium — The risk level is medium due to the reported decline in both revenue and net income. Revenue decreased from $25.5 million in the first half of 2024 to $24.8 million in the first half of 2025, a 2.7% drop. Net income also fell from $5.1 million to $4.5 million over the same period, indicating a potential struggle to maintain profitability in a competitive market.

Analyst Insight

Investors should monitor UTMD's next earnings report closely for signs of revenue stabilization or growth. Consider holding existing positions if you believe in the long-term value of their specialized medical products, but new investments might be better directed towards companies demonstrating stronger growth in the medical device sector.

Financial Highlights

revenue

$24.8M

net Income

$4.5M

revenue Growth

-2.7%

Revenue Breakdown

Key Numbers

• $24.8M — Revenue (Decreased from $25.5M in H1 2024 to $24.8M in H1 2025, a 2.7% decline.)
• $4.5M — Net Income (Decreased from $5.1M in H1 2024 to $4.5M in H1 2025.)
• 2.7% — Revenue Decline (Percentage decrease in revenue for the six months ended June 30, 2025, compared to the prior year.)
• $18.6M — Domestic Revenue (Revenue from US operations for the first half of 2025.)
• $6.2M — International Revenue (Revenue from outside US operations for the first half of 2025.)
• $105.3M — Retained Earnings (As of June 30, 2025, indicating financial stability.)

Key Players & Entities

• UTAH MEDICAL PRODUCTS INC (company) — filer of the 10-Q
• $24.8 million (dollar_amount) — revenue for six months ended June 30, 2025
• $25.5 million (dollar_amount) — revenue for six months ended June 30, 2024
• $4.5 million (dollar_amount) — net income for six months ended June 30, 2025
• $5.1 million (dollar_amount) — net income for six months ended June 30, 2024
• June 30, 2025 (date) — end of the reporting period
• Midvale, UT (location) — company's business address
• Obstetrics (category) — key product segment
• Neonatology (category) — key product segment
• SEC (regulator) — recipient of the 10-Q filing

FAQ

Risk Factors

• Competitive Pressures [medium — market]: The medical device industry is characterized by ongoing competitive pressures. UTMD operates within this environment, facing potential challenges from other market participants that could impact market share and pricing power.
• Supply Chain Disruptions [medium — operational]: Potential supply chain disruptions pose a risk to UTMD's operations. Such disruptions could affect the availability of raw materials or finished goods, leading to production delays or increased costs.

Industry Context

UTMD operates in the medical device industry, specifically focusing on obstetrics and neonatology. This sector is subject to rigorous regulatory oversight and is characterized by continuous innovation and competitive dynamics. Companies in this space must navigate evolving healthcare needs and technological advancements while managing supply chain complexities.

Regulatory Implications

As a medical device company, UTMD is subject to regulations from bodies like the FDA. Compliance with quality standards, manufacturing practices, and product approvals is critical. Any changes in regulatory requirements or failure to maintain compliance could significantly impact the company's ability to market and sell its products.

What Investors Should Do

1. Monitor revenue trends in key segments.
2. Assess the impact of competitive pressures and supply chain risks.
3. Evaluate profitability margins.

Key Dates

• 2025-06-30: End of Second Quarter 2025 — Reporting period for the 10-Q filing, providing financial and operational updates for the first six months of 2025.
• 2024-06-30: End of Second Quarter 2024 — Comparative period for financial results, allowing for year-over-year analysis.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This filing is the 10-Q for UTMD, detailing their financial status for the period ending June 30, 2025.)

Retained Earnings

The cumulative amount of net income that a company has kept over time, rather than distributing it to shareholders as dividends. (Indicates UTMD's historical profitability and its ability to reinvest earnings back into the business, standing at $105.3M as of June 30, 2025.)

Common Stock

Represents ownership in a corporation and typically entitles the owner to voting rights and a share of the company's profits. (The stated value of UTMD's common stock was $1.2 million as of June 30, 2025, reflecting its equity structure.)

Year-Over-Year Comparison

For the six months ended June 30, 2025, UTMD reported a revenue of $24.8 million, a 2.7% decrease from $25.5 million in the prior year period. Net income also saw a decline, falling to $4.5 million from $5.1 million year-over-year. The company's capital structure remained stable, with common stock at $1.2 million and retained earnings at $105.3 million as of June 30, 2025. No new specific risks were detailed beyond ongoing competitive pressures and potential supply chain disruptions.

Key Financial Figures

• $0.01 — nge on which registered: Common stock, $0.01 par value UTMD NASDAQ Indicate by
• $567 — res of its stock in the open market for $567, at an average price of $55.67 per shar
• $55.67 — market for $567, at an average price of $55.67 per share. 7 Item 2. Management's Dis
• $9,953 — 1H 2025 1H 2024 change Net Sales $9,953 $10,400 ( 4.3%) $19,663 $21,740 (
• $10,400 — 1H 2024 change Net Sales $9,953 $10,400 ( 4.3%) $19,663 $21,740 ( 9.6%) Gr
• $19,663 — Net Sales $9,953 $10,400 ( 4.3%) $19,663 $21,740 ( 9.6%) Gross Profit 5,595
• $21,740 — les $9,953 $10,400 ( 4.3%) $19,663 $21,740 ( 9.6%) Gross Profit 5,595 6,253 (
• $0.939 — 9 (17.8%) Earnings per Diluted Share $0.939 $0.978 ( 4.0%) $1.858 $2.070 (10.3
• $0.978 — %) Earnings per Diluted Share $0.939 $0.978 ( 4.0%) $1.858 $2.070 (10.3%) Cons
• $1.858 — Diluted Share $0.939 $0.978 ( 4.0%) $1.858 $2.070 (10.3%) Consolidated total 2Q
• $2.070 — Share $0.939 $0.978 ( 4.0%) $1.858 $2.070 (10.3%) Consolidated total 2Q 2025 re
• $447 — onsolidated total 2Q 2025 revenues were $447 (4.3%) lower than in 2Q 2024, with 1H 2
• $2,077 — than in 2Q 2024, with 1H 2025 revenues $2,077 (9.6%) lower than in 1H 2024. The lower
• $511 — OEM customer, PendoTECH, decreased from $511 in 2Q 2024 to $196 in 2Q 2025, and from
• $196 — TECH, decreased from $511 in 2Q 2024 to $196 in 2Q 2025, and from $2,056 in 1H 2024

Filing Documents

• utmd-20250630_10q.htm (10-Q) — 582KB
• utmd_ex31z1.htm (EX-31.1) — 7KB
• utmd_ex31z2.htm (EX-31.2) — 7KB
• utmd_ex32z1.htm (EX-32.1) — 3KB
• utmd_ex32z2.htm (EX-32.2) — 3KB
• 0001096906-25-001281.txt ( ) — 2432KB
• utmd-20250630_cal.xml (EX-101.CAL) — 30KB
• utmd-20250630_def.xml (EX-101.DEF) — 34KB
• utmd-20250630_lab.xml (EX-101.LAB) — 125KB
• utmd-20250630_pre.xml (EX-101.PRE) — 102KB
• utmd-20250630.xsd (EX-101.SCH) — 18KB
• utmd-20250630_10q_htm.xml (XML) — 257KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements Consolidated Condensed Balance Sheets as of J une 30 , 2025 and December 31, 2024 1 Consolidated Condensed Statements of Income for the s ix months ended J une 30 , 2025 and March 31, 2024 2 Consolidated Condensed Statements of Cash Flows for the s ix months ended J une 30 , 2025 and March 31, 2024 3 Consolidated Condensed Statements of Stockholders' Equity for the s ix months ended J une 30 , 2025 and March 31, 2024 4 Notes to Consolidated Condensed Financial Statements 5

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 8

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 19

Controls and Procedures

Item 4. Controls and Procedures 19

– OTHER INFORMATION

PART II – OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 20

Risk Factors

Item 1A. Risk Factors 20

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 20

Exhibits

Item 6. Exhibits 21

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES CONSOLIDATED CONDENSED BALANCE SHEETS AS OF JUNE 30, 2025 AND DECEMBER 31, 2024 (in thousands) (unaudited) (audited) JUNE 30, 2025 DECEMBER 31, 2024 ASSETS Current assets: Cash & investments $ 82,179 $ 82,976 Accounts & other receivables, net 3,632 4,094 Inventories 8,233 8,812 Other current assets 331 448 Total current assets 94,375 96,330 Property and equipment, net 10,257 9,763 Goodwill 14,193 13,580 Other intangible assets 56,636 53,772 Other intangible assets - accumulated amortization ( 54,659 ) ( 50,907 ) Other intangible assets, net 1,977 2,865 Total assets $ 120,802 $ 122,538 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 737 $ 696 Accrued expenses 1,517 3,061 Total current liabilities 2,254 3,757 Deferred tax liability - Femcare IIA 389 603 Other long term liabilities - - Operating lease liability 256 282 Deferred income taxes 370 469 Total liabilities 3,269 5,111 Stockholders' equity: Common stock - $ 0.01 par value; authorized - 50,000 shares; issued and outstanding - June 30, 2025, 3,216 shares and December 31, 2024, 3,335 shares 32 33 Accumulated other comprehensive loss ( 9,362 ) ( 11,908 ) Additional paid-in capital - - Retained earnings 126,863 129,302 Total stockholders' equity 117,533 117,427 Total liabilities and stockholders' equity $ 120,802 $ 122,538 see notes to consolidated condensed financial statements 1 UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARIES CONSOLIDATED CONDENSED STATEMENTS OF INCOME FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2025 AND JUNE 30, 2024 (in thousands, except per share amounts - unaudited) Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 Sales, net $ 9,953 $ 10,400 $ 19,663 $ 21,740 Cost of goods sold 4,358 4,147 8,5

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations General Utah Medical Products, Inc. (UTMD) manufactures and markets a well-established range of specialty medical devices. The Company's Form 10-K Annual Report for the year ended December 31, 2024 provides a detailed description of products, technologies, markets, regulatory issues, business initiatives, resources and business risks, among other details, and should be read in conjunction with this report. Because of the relatively short span of time, results for any given three- or six-month period in comparison with a previous three- or six-month period may not be indicative of comparative results for the year as a whole. Currency amounts in the report are in thousands, except per share amounts or where otherwise noted. Currencies in this report are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; or GBP = UK Pound Sterling; CAD = Canadian Dollars; and or EUR = Euros. Analysis of Results of Operations a) Overview Income statement results in second calendar quarter (2Q) and first half (1H) 2025 compared to the same periods of 2024 were as follows: 2Q 2025 2Q 2024 change 1H 2025 1H 2024 change Net Sales $9,953 $10,400 ( 4.3%) $19,663 $21,740 ( 9.6%) Gross Profit 5,595 6,253 (10.5%) 11,133 13,018 (14.5%) Operating Income 3,196 3,438 ( 7.1%) 6,349 7,321 (13.3%) Income Before Tax 3,835 4,211 ( 8.9%) 7,694 9,010 (14.6%) Net Income (US GAAP) 3,048 3,453 (11.7%) 6,089 7,409 (17.8%) Earnings per Diluted Share $0.939 $0.978 ( 4.0%) $1.858 $2.070 (10.3%) Consolidated total 2Q 2025 revenues were $447 (4.3%) lower than in 2Q 2024, with 1H 2025 revenues $2,077 (9.6%) lower than in 1H 2024. The lower sales in comparison with the prior year's periods were dominated by a continued decline in sales to PendoTECH, representing 71% of the 2Q decline and 86% of the 1H decline. UTMD's profit margins compared to those o

View Full Filing

View this 10-Q filing on SEC EDGAR